[ad_1]
Dynamic Technology Lab Private Ltd purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 1,470 shares of the medical instruments supplier’s stock, valued at approximately $329,000.
A number of other institutional investors also recently added to or reduced their stakes in the stock. DAVENPORT & Co LLC grew its stake in shares of West Pharmaceutical Services by 103.8% in the 1st quarter. DAVENPORT & Co LLC now owns 2,230 shares of the medical instruments supplier’s stock valued at $499,000 after purchasing an additional 1,136 shares during the period. Robeco Institutional Asset Management B.V. grew its stake in shares of West Pharmaceutical Services by 34.7% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 5,581 shares of the medical instruments supplier’s stock valued at $1,249,000 after purchasing an additional 1,437 shares during the period. Bessemer Group Inc. grew its stake in shares of West Pharmaceutical Services by 43.7% in the 1st quarter. Bessemer Group Inc. now owns 1,075 shares of the medical instruments supplier’s stock valued at $241,000 after purchasing an additional 327 shares during the period. Polar Asset Management Partners Inc. grew its stake in shares of West Pharmaceutical Services by 106.5% in the 1st quarter. Polar Asset Management Partners Inc. now owns 53,070 shares of the medical instruments supplier’s stock valued at $11,881,000 after purchasing an additional 27,370 shares during the period. Finally, Sivik Global Healthcare LLC bought a new stake in shares of West Pharmaceutical Services in the 1st quarter valued at approximately $2,799,000. 93.90% of the stock is owned by institutional investors and hedge funds.
West Pharmaceutical Services Stock Down 3.9%
NYSE:WST opened at $253.50 on Friday. The stock’s fifty day moving average price is $241.04 and its two-hundred day moving average price is $225.38. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $352.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.08 and a current ratio of 2.78. The company has a market cap of $18.23 billion, a price-to-earnings ratio of 37.95, a P/E/G ratio of 4.68 and a beta of 1.05.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.33. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.The firm had revenue of $766.50 million for the quarter, compared to the consensus estimate of $725.11 million. During the same quarter in the prior year, the business earned $1.52 EPS. The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. On average, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.
West Pharmaceutical Services Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 19th. Shareholders of record on Wednesday, November 12th will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.88 annualized dividend and a yield of 0.3%. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.21. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 12.57%.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Barclays assumed coverage on West Pharmaceutical Services in a research note on Tuesday, June 24th. They issued an “equal weight” rating and a $245.00 price objective on the stock. Evercore ISI upped their price objective on West Pharmaceutical Services from $275.00 to $350.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. UBS Group upped their price objective on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Finally, Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $320.71.
Get Our Latest Analysis on West Pharmaceutical Services
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for West Pharmaceutical Services and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link